The physiological significance of the endoendothelial fibrin lining (EEFL) as the critical interface in the ‘vessel-blood organ’ and the importance of in vivo ‘fibrinogenin formation’ in health and disease

Fibrinogen-containing membrane-associated structures arising at the surfaces of ADP-stimulated blood platelets

Ultrastructural studies of ADP-stimulated gel-filtered human platelets incubated with different concentrations of fibrinogen reveal unusual extracellular structures composed at least partly of the aggregated fibrinogen. Development of these structures depends on the exogenous fibrinogen concentration and duration of the incubation. Fibrinogen-containing extracellular material exists in two different structural forms. As was shown earlier, one of them is represented by dense, amorphous intercellular matrix and is localized mainly in platelet microaggregates (Belitser et al., Thromb. Res., in press). Another one consists of huge sheet-like structures bearing individual or clumped platelets bound either to one or to both of their surfaces. After thrombin treatment, these structures could not be found anymore; sometimes they seem to be substituted by the fibrin-like fibers spatially connected to each other and/or to the platelet membranes. It has been suggested that soluble fibrinogen interacting with its specific membrane receptors undergoes conformational changes promoting intermolecular interactions and resulting in the fibrinogen aggregates formation at the surfaces of the activated platelets. A probable physiological significance of the structures described is discussed. It is supposed that under certain conditions in vivo they may play an important role, in particular as a highly concentrated substrate for the thrombin action, providing in such a way a possibility of rapid, effective consolidation of the initial platelet thrombi with the fibrin fibers.

Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Use of monoclonal antibodies

Samples of normal and atherosclerotic vessels obtained from vascular and cardiothoracic surgery were examined for the distribution of fibrinogen/fibrin I, fibrin II, and fibrin(ogen) degradation products (Fragment D/DD) by using recently characterized monoclonal antibodies that recognize and distinguish the three molecular forms (MAbs 18C6, T2G1, and GC4, respectively) with the ABC-immunoperoxidase technique. In normal aortas, little fibrinogen/fibrin I or fibrin II was present and no fibrin(ogen) degradation products could be detected. In early lesions and in fibrous plaques, fibrinogen/fibrin I and fibrin II were distributed in long threads and surrounding vessel wall cells and macrophages. Fibrin(ogen) degradation products were not seen in early lesions. In fibrous and advanced plaques, fibrinogen/fibrin I, fibrin II, and fibrin(ogen) degradation products were detected in areas of loose connective tissue, in thrombus, and around cholesterol crystals. The results of this study suggest that increased fibrin formation and degradation may be associated with progression of atherosclerotic disease. The observed distribution of the different molecular forms of fibrinogen also suggests the possibility that the cells present in the lesions actively participate in the fibrinogen-to-fibrin transition within the vessel wall.

Fibrinogen coagulation without thrombin: reaction with vitamin C and copper(II)

We describe a novel method for inducing fibrinogen derived clots. The addition of vitamin C (0.1-1 mM) to a solution of fibrinogen (1 mg/ml) and Cu(II) (20-150 microM) results in protein coming out of solution. This phenomenon can be "read" by fibrometers as "clotting time". The reaction requires Cu(II) and can be prevented by a chelating agent, such as citrate, as well by a hydroxyl radical scavenger, such as mannitol. The insoluble protein, called "neofibe", is soluble in 4 M urea and 2% SDS. Isoelectric focusing and SDS-electrophoretic comparison of native fibrinogen with neofibe reveal molecular modifications of the starting protein. This reaction is an interesting example of a free radical mediated transformation of soluble protein into insoluble material. Some findings on the connection between hemostasis, vitamin C and Cu(II) are discussed.

A survey of surface hemorheological experiments on the inhibition of fibrinogenin formation employing surface layers of fibrinogen systems with heparins and other substances. A contribution on antithrombogenic action

In earlier studies using a modified Weissenberg Rheogoniometer, we found decreased rigidity or torque values (tau) in surface layers of heparin plasma, when compared to tau of oxalate plasma from the same blood withdrawal (Thrombosis Res. 1, 1-17, 1972). In subsequent studies of the viscoelasticity of surface layers of highly purified fibrinogen (97-100% clottability) of human and bovine origin, we found, with some heparins, marked lowering of surface viscous moduli (eta's) and of surface elastic moduli (Gs). With some heparins no changes in tau, eta's and Gs occurred. Certain low molecular weight (LMW) preparations of heparins showed decreases, but some did not. This is also the case with heparins of low and high affinity for antithrombin. Calcium heparin and Ca2+ alone always increased eta's and Gs, when added to the fibrinogen system. N-desulfated heparin both decreased or did not change eta's and Gs. Preparations of fibrinogen in dog plasma, to which sodium heparin was added, resulted in a decrease of tau values. These results appear to emphasize that plasma proteins other than fibrinogen, and other plasma constituents, may affect surface hemorheological values. These findings suggest needed interface studies of fibrinogen systems to which plasma or plasma constituents are added. We found also that other substances, i.e., dextran MW 20,000; dextran sulfate MW 17,000; sodium hyaluronate and depolymerized hyaluronate decreased tau, eta's and Gs markedly. Recent findings in the literature are discussed in relation to thrombogenesis in which fibrinogenin gelation is considered as the initial phase of blood clotting. Fibrinogenin is the new term for initial fibrinogen aggregation and subsequent fibrinogen gelation without thrombin participation. The inhibition of fibrinogenin formation extra vivum is considered to be a valid indicator of antithrombogenic activity of substances which play a significant role in investigations on the therapy and prevention of thrombotic conditions.